Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) Director Sells $326,553.90 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,778 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the transaction, the director directly owned 2,778 shares of the company’s stock, valued at $326,553.90. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Simon Read also recently made the following trade(s):

• On Monday, August 10th, Simon Read sold 2,777 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $109.55, for a total transaction of $304,220.35.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $111.10 on Friday. The business has a 50-day moving average of $100.75 and a two-hundred day moving average of $84.99. The firm has a market capitalization of $6.07 billion, a PE ratio of -26.77 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12 month low of $22.76 and a 12 month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Analysts Set New Price Targets

DNTH has been the subject of several research reports. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $27,000. First Horizon Corp acquired a new position in shares of Dianthus Therapeutics during the first quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth $40,000. EFG International AG purchased a new position in shares of Dianthus Therapeutics in the second quarter valued at $49,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics in the third quarter valued at $64,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.